tradingkey.logo
tradingkey.logo
Search

Precigen Inc

PGEN
Add to Watchlist
4.150USD
+0.070+1.72%
Close 05/13, 16:00ETQuotes delayed by 15 min
1.45BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+1.72%

5 Days

-5.68%

1 Month

-0.48%

6 Months

+7.51%

Year to Date

-0.72%

1 Year

+207.41%

TradingKey Stock Score of Precigen Inc

Currency: USD Updated: 2026-05-13

Key Insights

Precigen Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.50.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Precigen Inc's Score

Industry at a Glance

Industry Ranking
73 / 156
Overall Ranking
191 / 4487
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Precigen Inc Highlights

StrengthsRisks
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Fairly Valued
The company’s latest PE is -3.43, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 270.08M shares, increasing 5.66% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 17.96K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.23.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
9.500
Target Price
+126.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Precigen Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Precigen Inc Info

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Ticker SymbolPGEN
CompanyPrecigen Inc
CEOSabzevari (Helen)
Websitehttps://precigen.com/
KeyAI